Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00219297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer.
Study identification
- NCT ID
- NCT00219297
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Patupilone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2005
- Primary completion
- Jun 23, 2010
- Completion
- Jun 23, 2010
- Last update posted
- Feb 20, 2021
2005 – 2010
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Cancer Center UC Davis Cancer (3) | Sacramento | California | 95817 | — |
| Dana Farber Cancer Institute SC | Boston | Massachusetts | 02115 | — |
| Wayne State University/Wertz Clinical Cancer Center Div. of Hematology/Oncology | Detroit | Michigan | 48201 | — |
| St Louis University Cancer Center | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine-Siteman Cancer Ctr | St Louis | Missouri | 63110 | — |
| Dartmouth Hitchcock Medical Center Oncology | Lebanon | New Hampshire | 03756 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| Columbia University Medical Center New York Presbyterian | New York | New York | 10032 | — |
| Duke University Medical Center Dept. of DUMC (3) | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00219297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2021 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00219297 live on ClinicalTrials.gov.